Related Experiment Video
Updated: Jun 18, 2026
09:00
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
Published on: March 18, 2015
Corynoxine suppresses hepatocellular carcinoma progression by forming the ROS-STAT3 cycle
Chunmei Wen1, Mengyao Wang1, Yitian Yu2
1Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Toxicology and Applied Pharmacology
|June 16, 2026
Summary
Corynoxine (Cory) inhibits hepatocellular carcinoma (HCC) progression by promoting ROS production and suppressing the JAK2/STAT3 pathway. This natural compound shows promise as a novel therapeutic agent for HCC treatment.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent malignancy with poor outcomes.
- Corynoxine (Cory), from Uncaria rhynchophylla, is an autophagy enhancer with unknown effects in HCC.
Purpose of the Study:
- Investigate the anti-tumor effects of Cory in HCC.
- Elucidate the underlying mechanisms of Cory's action in HCC.
Main Methods:
- Utilized HepG2 and Huh7 HCC cell lines for in vitro studies.
- Employed a xenograft mouse model for in vivo validation.
- Assessed cell growth, migration, invasion, apoptosis, ROS production, and JAK2/STAT3 signaling.
Main Results:
- Cory significantly suppressed HCC cell growth, migration, and invasion while inducing apoptosis.
- Cory promoted intracellular ROS production and inhibited the JAK2/STAT3 pathway.
- A positive feedback loop between ROS and STAT3, activated by Cory, was identified.
- In vivo studies confirmed Cory's tumor growth retardation via ROS and STAT3 modulation.
Conclusions:
- Cory impedes HCC progression through a ROS-STAT3 positive feedback loop.
- Cory exhibits potential as a therapeutic candidate for hepatocellular carcinoma treatment.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...